# Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma

Source: https://onco.cc/trials/nct07545603/  
OnCo record `nct07545603` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of XNW5004 in follicular lymphoma, run by Evopoint Biosciences Inc., now recruiting.

## Summary

Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma is a phase 2 interventional study registered as NCT07545603 by Evopoint Biosciences Inc., with 65 participants planned, started 2026-02-14 and due to reach its primary completion in 2027-12-31. Interventions recorded: XNW5004 tablets. Conditions listed: Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2, Follicular Lymphoma, Grade 3, Follicular Lymphoma Grade 3A. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07545603
- Phase: 2
- Setting: Phase II Study of XNW5004 in the Treatment of Patients With Relapsed or Refractory Follicular Lymphoma (EZH2 Wild-type)
- Sponsor: Evopoint Biosciences Inc.
- Enrolled: 65

## Sources

- ClinicalTrials.gov NCT07545603: https://clinicaltrials.gov/study/NCT07545603

## Connected records

- cancers: [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- drugs: [XNW5004](https://onco.cc/drugs/xnw5004/)
- companies: [Evopoint Biosciences](https://onco.cc/companies/evopoint-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct07545603.json